We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
-12.62%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$187M
AUM Growth
-$54.5M
Cap. Flow
-$15.7M
Cap. Flow %
-8.39%
Top 10 Hldgs %
100%
Holding
12
New
1
Increased
–
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
UTRS
Minerva Surgical, Inc. Common Stock
UTRS
+$11.9M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$10.1M
2
APRE icon
Aprea Therapeutics
APRE
+$6.44M
3
FLXN
Flexion Therapeutics, Inc.
FLXN
+$6.1M
4
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$4.92M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GRTS
1
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$45.8M 24.49%
3,561,150
-444,744
-11% -$4.92M
CRSP icon
2
CRISPR Therapeutics
CRSP
$4.68B
$37.8M 20.21%
498,558
– –
PASG icon
3
Passage Bio
PASG
$14.7M
$31.5M 16.84%
247,988
– –
ALGS icon
4
Aligos Therapeutics
ALGS
$26.3M
$27.5M 14.73%
92,815
– –
AKRO
5
DELISTED
Akero Therapeutics
AKRO
$13.1M 6.99%
617,727
– –
CRNX icon
6
Crinetics Pharmaceuticals
CRNX
$8.88B
$11.7M 6.24%
410,360
-410,360
-50% -$10.1M
ADVM
7
DELISTED
Adverum Biotechnologies
ADVM
$8.92M 4.77%
506,823
– –
UTRS
8
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$8.6M 4.6%
+83,685
New +$11.9M
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
$1.84M 0.98%
543,753
– –
CLVS
10
DELISTED
Clovis Oncology, Inc.
CLVS
$276K 0.15%
101,855
– –
APRE icon
11
Aprea Therapeutics
APRE
$7.6M
– –
-62,983
Closed -$6.44M
FLXN
12
DELISTED
Flexion Therapeutics, Inc.
FLXN
– –
-1,000,000
Closed -$6.1M

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q4 2021 Portfolio in Review

As of Q4 2021, Versant Venture Management held 12 positions worth $187M, down 23% from $242M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $15.7M in Q4 2021, closing 2 positions and reducing 2 holdings. Its most notable exit was Aprea Therapeutics, an estimated $6.44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Versant Venture Management opened a new position in Minerva Surgical, Inc. Common Stock worth $8.6M.

  • Versant Venture Management's largest Q4 2021 buy was Minerva Surgical, Inc. Common Stock: 83,685 shares worth $8.6M.
  • Versant Venture Management's biggest Q4 2021 reduction was Crinetics Pharmaceuticals, cutting an estimated $10.1M.
  • Versant Venture Management fully exited Aprea Therapeutics in Q4 2021, selling an estimated $6.44M.
  • Versant Venture Management's ten largest holdings make up 100% of its $187M portfolio in Q4 2021.
  • Versant Venture Management opened 1 new position and closed 2 in Q4 2021.
  • Versant Venture Management's portfolio value fell 23% quarter-over-quarter to $187M.

Based on Versant Venture Management's 13F filing for Q4 2021, filed 11 Feb 2022.